Sept. 24, 2020 Price forecast | 2 weeks: -0.66% | 1 month: -1.32% | 3 months: 0.39%


EBS stock forecast

Our latest prediction for Emergent BioSolutions, Inc.'s stock price was made on the Sept. 24, 2020 when the stock price was at 99.11$.

In the short term (2weeks), EBS's stock price should underperform the market by -0.66%. During that period the price should oscillate between -6.63% and +7.44%.

In the medium term (3months), EBS's stock price should outperform the market by 0.39%. During that period the price should oscillate between -21.39% and +16.99%.

Create a solid portfolio with EBS

Add EBS to your portfolio and optimize it!


About Emergent BioSolutions, Inc.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.

At the moment the company generates 1259M USD in revenues.

On its last earning announcement, the company reported a profit of 3.24$ per share.

The book value per share is 18.76$

Emergent BioSolutions, Inc. website


Three months stock forecastSept. 24, 2020


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
1259M 64.50% 262M 20.90% 170M 3.24 - - 53M 18.76 304M -111M 194M